Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.
暂无分享,去创建一个
M. Harrison | Rajan T. Gupta | A. Armstrong | F. Schwartz | D. George | Yuan Wu | Dylan Zhang | Ethan Ho | Danielle E. Kruse | H. McManus | J. Infield | Danielle Kruse | Danielle E Kruse
[1] S. Signoretti,et al. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.
[2] R. Motzer,et al. Associations between body composition features and clinical outcomes in metastatic clear cell renal cell carcinoma patients treated with immune checkpoint blockade. , 2022, Clinical Cancer Research.
[3] Said Pertuz,et al. Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review. , 2021, European journal of radiology.
[4] V. Master,et al. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors , 2021, Frontiers in Oncology.
[5] T. Choueiri,et al. Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. , 2021, JAMA oncology.
[6] Shannon K. Boi,et al. Obesity diminishes response to PD-1-based immunotherapies in renal cancer , 2020, Journal for ImmunoTherapy of Cancer.
[7] S. Hancock,et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[8] Mirza Faisal Beg,et al. Deep learning method for localization and segmentation of abdominal CT , 2020, Comput. Medical Imaging Graph..
[9] H. Lau,et al. A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes. , 2020, The Journal of urology.
[10] G. Valabrega,et al. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy , 2020, International journal of molecular sciences.
[11] J. Meyerhardt,et al. Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients , 2020, Journal of cachexia, sarcopenia and muscle.
[12] R. Motzer,et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. , 2019, The Lancet. Oncology.
[13] E. Giovannucci,et al. The Obesity Paradox in Cancer: Epidemiologic Insights and Perspectives , 2019, Current Nutrition Reports.
[14] L. Crinò,et al. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab , 2019, Clinical Cancer Research.
[15] E. Philip,et al. Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma , 2019, Kidney Cancer.
[16] Justin C. Brown,et al. The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers , 2018, Journal of cachexia, sarcopenia and muscle.
[17] B. Tan,et al. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis , 2018, Gastric Cancer.
[18] B. Escudier,et al. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma , 2018, Drugs.
[19] B. Caan,et al. The Obesity Paradox in Cancer: How Important Is Muscle? , 2018, Annual review of nutrition.
[20] B. Caan,et al. The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint. , 2018, Cancer research.
[21] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[22] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[23] L. Kiemeney,et al. Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis. , 2016, European urology focus.
[24] D. Ye,et al. Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients , 2017, Scientific Reports.
[25] S. Signoretti,et al. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Muss,et al. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. , 2016, European journal of cancer.
[27] Martin Jägersand,et al. Body Composition Assessment in Axial CT Images Using FEM-Based Automatic Segmentation of Skeletal Muscle , 2016, IEEE Transactions on Medical Imaging.
[28] C. Prado,et al. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact , 2016, Proceedings of the Nutrition Society.
[29] M. Kuczyk,et al. Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study , 2013, International journal of urology : official journal of the Japanese Urological Association.
[30] H. Adami,et al. Body mass index and survival in patients with renal cell carcinoma: A clinical‐based cohort and meta‐analysis , 2013, International journal of cancer.
[31] Paula Ravasco,et al. Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.
[32] L. Birdsell,et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[34] R. Ross,et al. Human body composition: advances in models and methods. , 1997, Annual review of nutrition.